Advertisement

Rheumatology International

, Volume 39, Issue 4, pp 585–593 | Cite as

Mexican rheumatology: where do we stand?

  • Carlos PinedaEmail author
  • Hugo Sandoval
  • Antonio Fraga-Mouret
Review
  • 49 Downloads

Abstract

The aim of this review was to provide an overall overview of the past, present, and future situations and main challenges that are facing Mexican Rheumatology as a medical subspecialty in the context of their national healthcare system, where a deficit of workforce at the national level coexists with a shortage of specialists in the less-developed southern states of the country and a great surplus of professionals within large metropolitan areas. We also analyzed the prevalence and burden of Rheumatic and Musculoskeletal Diseases (RMDs), the structural composition and distribution of Mexican Rheumatology, and the clinical profile of the Mexican Rheumatologist. Last, we examined comorbidities, education and training programs and one scenario for Mexican Rheumatology wherein the principal main threats and opportunities are determined.

Keywords

Health services Medical staff Mexico Rheumatology Musculoskeletal diseases 

Notes

Author contributions

All authors were involved in drafting the article or revising it critically for important intellectual content. All authors approved the final version to be submitted for publication.

Compliance with ethical standards

Conflict of interest

The authors report no relationships that could be construed as a conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    Worldometers Countries in the world by population (2018) http://www.worldometers.info/world-population/population-by-country/. Accessed 6 Feb 2018
  2. 2.
    United Nations World Population Prospects (2017) https://esa.un.org/unpd/wpp/Download/Standard/Population/. Accessed 5 Feb 2018
  3. 3.
    Cardiel MH (2006) First Latin American position paper on the pharmacological treatment of rheumatoid arthritis. Rheumatology 45(Suppl 2):ii7–ii22Google Scholar
  4. 4.
    Pineda C, Sandoval H (2017) Defining quality of rheumatologic care: Mexico. J Clin Rheumatol 23(4):209–211CrossRefGoogle Scholar
  5. 5.
    OECD (2016) OECD reviews of health systems: Mexico 2016. OECD Publishing, ParisGoogle Scholar
  6. 6.
    Cardiel MH, Díaz-Borjoón A, Vázquez del Mercado Espinosa M et al (2014) Update of the Mexican College of Rheumatology guidelines for the pharmacologic treatment of rheumatoid arthritis. Reumatol Clin 10(4):227–240CrossRefGoogle Scholar
  7. 7.
    Badia Flores JJ, Arévalo Martínez FG (2009) Reumatólogos mexicanos. Distribución nacional del año 2007 y proyección al 2025. Reumatol Clin 5(3):140–141CrossRefGoogle Scholar
  8. 8.
    Loyola-Sánchez A, Richardson J, Peláez-Ballestas I et al (2017) Physical function assessment of a Mayan population living with osteoarthritis: the importance of considering different aspects of functioning. Rehabil Process Outcome 6:1–9CrossRefGoogle Scholar
  9. 9.
    Álvarez-Nemégyei J, Peláez-Ballestas I, Goñi M et al (2016) Prevalence of rheumatic regional pain syndromes in Latin-American indigenous groups: a census study based on COPCORD methodology and syndrome-specific diagnostic criteria. Clin Rheumatol 35:63–70CrossRefGoogle Scholar
  10. 10.
    Del Río Nájera D, González-Chávez SA, Quinoñez-Flores CM, Peláez-Ballestas I, Hernández-Nájera N, Pacheco-Tena CF (2016) Rheumatic diseases in Chihuahua, Mexico: a COPCORD Survey. J Clin Rheumatol 22(4):188–193CrossRefGoogle Scholar
  11. 11.
    Hernández-Cáceres AE, Rodríguez-Amado J, Peláez-Ballestas I, Vega-Morales D, Garza-Elizondo MA (2015) Factors associated with treatment of osteoarthritis: analysis of a COPCORD study in Nuevo Leon, Mexico. Reumatol Clin 11(4):204–209CrossRefGoogle Scholar
  12. 12.
    Moreno-Montoya J, Álvarez-Nemégyei J, Trejo-Valdívia B, Peláez-Ballestas I (2014) Assessment of the dimensions, construct validity, and utility for rheumatoid arthritis screening of the COPCORD instrument. Clin Rheumatol 33(5):631–636CrossRefGoogle Scholar
  13. 13.
    Burgos-Vargas R, Cardiel MH, Loyola-Sánchez A et al (2014) Characterization of knee osteoarthritis in Latin America. A comparative analysis of clinical and health care utilization in Argentina, Brazil, and Mexico. Reumatol Clin 10(3):152–159CrossRefGoogle Scholar
  14. 14.
    Álvarez-Nemégyei J, Peláez-Ballestas I, Rodríguez-Amado J et al (2011) Prevalence of rheumatic regional pain syndromes in adults from Mexico: a community survey using COPCORD for screening and syndrome-specific diagnostic criteria. J Rheumatol Suppl 86:15–20Google Scholar
  15. 15.
    Álvarez-Nemégyei J, Peláez-Ballestas I, Sanin LH, Cardiel MH, Ramírez-Angulo A, Goycochea-Robles MV (2011) Prevalence of musculoskeletal pain and rheumatic diseases in the southeastern region of Mexico. A COPCORD-based community survey. J Rheumatol Suppl 86:21–25Google Scholar
  16. 16.
    Cardiel MH, Rojas-Serrano J (2002) Community based study to estimate prevalence, burden of illness and help seeking behavior in rheumatic diseases in Mexico City. A COPCORD study. Clin Exp Rheumatol 20(5):617–624Google Scholar
  17. 17.
    Bennett K, Cardiel MH, Ferraz MB, Riedemann P, Goldsmith CH, Tugwell P (1997) Community screening for rheumatic disorder: cross cultural adaptation and screening characteristics of the COPCORD core questionnaire in Brazil, Chile, and Mexico. The PANLAR-COPCORD Working Group. Pan American League of Associations for Rheumatology. Community Oriented Programme for the Control of Rheumatic Disease. J Rheumatol 24(1):160–168Google Scholar
  18. 18.
    Courage UU, Stephen DP, Lucius IC et al (2017) Prevalence of musculoskeletal diseases in a semi-urban Nigerian community: results of a cross-sectional survey using COPCORD methodology. Clin Rheumatol 36(11):2509–2516CrossRefGoogle Scholar
  19. 19.
    Peláez-Ballestas I, Sanin LH, Moreno-Montoya J et al (2011) Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology. J Rheumatol 86:3Google Scholar
  20. 20.
    Peláez-Ballestas I, Álvarez-Nemégyei J, Loyola-Sánchez A, Escudero ML (2016) Prevalence and factors associated with musculoskeletal disorders and rheumatic diseases in indigenous Maya-Yucateco people: a cross-sectional community-based study. Clin Rheumatol 35(1):15–23CrossRefGoogle Scholar
  21. 21.
    Kumar B (2017) Global health inequities in rheumatology. Rheumatology 56(1):4–5CrossRefGoogle Scholar
  22. 22.
    Global Burden of Disease Collaborative Network Global Burden of Disease Study (2018) 2016 results institute for health metrics and evaluation, 2017. http://ghdx.healthdata.org/gbd-results-tool. Accessed 7 Mar 2018
  23. 23.
    World Health Organization Global Health Estimates Summary Tables: Projections of Deaths by Cause, Age and Sex by World Bank Income Category and WHO Region. World Health Organization (2013) http://www.who.int/healthinfo/global_burden_disease/GHE_DthWHOReg7_Proj_2015_20 30.xls?ua = 1. Accessed 5 Mar 2018
  24. 24.
    Reveille JD, Muñoz R, Soriano E et al (2016) Review of current workforce for rheumatology in the countries of the Americas 2012–2015. J Clin Rheumatol 22(8):405–410CrossRefGoogle Scholar
  25. 25.
    Al Maini M, Adelowo F, Al Saleh J et al (2015) The global challenges and opportunities in the practice of rheumatology: white paper by the World Forum on Rheumatic and Musculoskeletal Diseases. Clin Rheumatol 34(5):819–829CrossRefGoogle Scholar
  26. 26.
    Saavedra-Salinas MA, Barrera-Cruz A, Cabral-Castañeda AR et al (2015) Clinical practice guidelines for the management of pregnancy in women with autoimmune rheumatic diseases of the Mexican College of Rheumatology. Part I. Reumatol Clin 115:295–304CrossRefGoogle Scholar
  27. 27.
    Saavedra-Salinas MA, Barrera-Cruz A, Cabral-Castañeda AR et al (2015) Clinical practice guidelines for the management of pregnancy in women with autoimmune rheumatic diseases of the Mexican College of Rheumatology. Part II. Reumatol Clin 11(5):305–315CrossRefGoogle Scholar
  28. 28.
    Bori-Segura G, Hernández-Cruz B, Gobbo M et al (2009) Appropriate use of non-steroidal anti-inflammatory drugs in rheumatology: guidelines from the Spanish Society of Rheumatology and the Mexican College of Rheumatology. Reumatol Clin 5(1):3–12CrossRefGoogle Scholar
  29. 29.
    Comité Mexicano del Consenso de Biológicos (2006) Guías y recomendaciones del Colegio Mexicano de Reumatología para el uso de agentes biológicos en enfermos reumáticos. Reumatol Clin 2(2):78–89CrossRefGoogle Scholar
  30. 30.
    Miranda-Limón J (2005) Novedades terapéuticas en reumatología. Reumatol Clin 1(Supl 2):S1–S2CrossRefGoogle Scholar
  31. 31.
    Jara LJ, Barrera A (2006) Afección renal en la esclerosis sistémica. Reumatol Clin 2:S20–S23CrossRefGoogle Scholar
  32. 32.
    Monográfico osteoartritis (2007) Reumatol Clin Supl 3(SE3):1–69Google Scholar
  33. 33.
    Monográfico Miopatías inflamatórias (2009) Reumatol Clin Supl 5(S3):1–40Google Scholar
  34. 34.
    Monográfico vasculitis (2011) Reumatol Clin Supl 7(S3):1–46Google Scholar
  35. 35.
    Anatomía Clínica Musculoesquelética (2012) Reumatol Clin Supl 8(S2):1–52Google Scholar
  36. 36.
    García-Méndez S, Arreguín-Reyes R, López-López O, Vázquez-Mellado J (2014) Frequency of gout according to the perception of physicians in Mexico. Reumatol Clin 10(3):197–198CrossRefGoogle Scholar
  37. 37.
    Quintiles IMS (2017) The impact of biosimilar competition in Europe. http://www.medicinesforeurope.com/wp-content/uploads/2017/05/IMS-Biosimilar-2017_V9.pdf. Accessed 4 Apr 2018
  38. 38.
    Mulcahy AW, Predmore Z, Mattke S (2014) The cost savings potential of biosimilar drugs in the United States. Rand Corporation. https://www.rand.org/content/dam/rand/pubs/perspectives/PE100/PE127/RAND_PE127.pdf. Accessed 2 Apr 2018
  39. 39.
    García R, Araujo DV (2016) The regulation of biosimilars in Latin America. Curr Rheumatol Rep 18(3):16CrossRefGoogle Scholar
  40. 40.
    Espinosa-Morales R, Díaz-Borjón A, Barile-Fabris LA et al (2013) Biosimilar drugs in Mexico: position of the Mexican College of Rheumatology, 2012. Reumatol Clin 9(2):113–116CrossRefGoogle Scholar
  41. 41.
    Xibille D, Carrillo S, Huerta-Sil G et al (2018) Escenario actual de los medicamentos biocomparables en México: posicionamiento del Colegio Mexicano de Reumatología, 2016. Reumatol Clin 14(3):127–136CrossRefGoogle Scholar
  42. 42.
    Descalzo M, Carmona L (2010) Biobadaser 2.0: analysis and trends in 2009. Reumatol Clin (English Edition) 6(5):240–243CrossRefGoogle Scholar
  43. 43.
    Sánchez-Piedra C, Hernández-Miguel MV, Manero J et al (2017) Objectives and methodology of BIOBADASER phase iii. Reumatol Clin.  https://doi.org/10.1016/j.reuma.2017.08.001 Google Scholar
  44. 44.
    Biobadamerica (2018) Registro Panamericano de acontecimientos adversos de terapias biológicas en enfermedades reumáticas. BIOBADASER. https://biobadaser.ser.es/biobadamerica/. Accessed 1 Apr 2018
  45. 45.
    Barile Fabris LA (2016) Registro Mexicano de Acontecimientos Adversos de Terapias Biológicas y Biocomparables en Enfermedades Reumáticas. Protocolo de Estudio. Colegio Mexicano de Reumatología, AC. https://docs.wixstatic.com/ugd/9c7f2b_a517391bd3e548529ddb19f562c1d12b.pdf. Accessed 22 June 2018
  46. 46.
    International Federation of Pharmaceutical Manufacturers Associations (2014) Policy statement. Non-comparable biotherapeutic products. IFPMA Geneva, Switzerland. http://www.ifpma.org/wp-content/uploads/2016/02/Non-comparable_Biotherapeutic_Products__English__02.pdf. Accessed 25 Mar 2018
  47. 47.
    Pineda C, Caballero-Uribe CV, de Oliveira MG et al (2015) Recommendations on how to ensure the safety and effectiveness of biosimilars in Latin America: a point of view. Clin Rheumatol 34(4):635–640CrossRefGoogle Scholar
  48. 48.
    Bennett CL, Chen B, Hermanson T et al (2014) Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol 15(13):e594–e605CrossRefGoogle Scholar
  49. 49.
    Galarza-Delgado DA, Azpíri-López JR, Colunga-Pedraza IJ et al (2017) Prevalence of comorbidities in Mexican mestizo patients with rheumatoid arthritis. Rheumatol Int 37(9):1507–1511CrossRefGoogle Scholar
  50. 50.
    Bautista-Molano W, Landewe R, Burgos-Vargas R et al (2018) Prevalence of comorbidities and risk factors for comorbidities in patients with spondyloarthritis in Latin America: a comparative study with the general population and data from the ASAS-COMOSPA study. J Rheumatol 45(2):206–212CrossRefGoogle Scholar
  51. 51.
    Muñoz-Louis R, Medrano-Sánchez J, Montufar R (2015) Rheumatoid arthritis in Latin America: challenges and solutions to improve its diagnosis and treatment training for medical professionals. Clin Rheumatol 34(Suppl 1):S67–S70CrossRefGoogle Scholar
  52. 52.
    Saavedra MA, Villaseñor-Óvies P, Harfush LA et al (2016) Educational impact of a clinical anatomy workshop on 1st-year orthopedic and rheumatology fellows in Mexico city. Clin Rheumatol 35(5):1299–1306CrossRefGoogle Scholar
  53. 53.
    Pineda C, Filippucci E, Chávez-López M et al (2008) Ultrasound in rheumatology. The Mexican experience. Clin Exp Rheumatol 26(5):929–932Google Scholar
  54. 54.
    Chávez-López M, Pineda C (2012) Musculoskeletal ultrasound in Mexico 10 years after its inception. Reumatol Clin 8(6):304–305CrossRefGoogle Scholar
  55. 55.
    Pineda C, Reginato AM, Flores V et al (2010) Pan-American League of Associations for Rheumatology (PANLAR) recommendations and guidelines for musculoskeletal ultrasound training in the Americas for rheumatologists. J Clin Rheumatol 16(3):113–118CrossRefGoogle Scholar
  56. 56.
    Pineda C, Sandoval H (2017) Impactos probables de la reforma migratoria estadounidense: algunos escenarios para la reumatología mexicana. Reumatol Clin 13(4):185–188CrossRefGoogle Scholar
  57. 57.
    Centers for Disease Control and Prevention (2018) CDC yellow book 2018: health information for international travel. https://wwwnc.cdc.gov/travel/yellowbook/2018/select-destinations/mexico. Accessed 18 May 2018
  58. 58.
    Promexico (2018) Health tourism. http://www.promexico.gob.mx/documentos/sectores/health-tourism.pdf. Accessed 14 May 2018
  59. 59.
    van Laar JM (2017) Rheumatology post-Brexit. Rheumatology 56(1):1–3CrossRefGoogle Scholar
  60. 60.
    Treviño CV, Cruzalta AA (1997) Las enfermedades reumáticas entre los nahuas prehispánicos. Estud Cult Náhuatl 27:528Google Scholar
  61. 61.
    Muriel J (1990) Hospitales de la Nueva España: Fundaciones del siglo XVI. Universidad Nacional Autónoma de México, MexicoGoogle Scholar
  62. 62.
    De la Cruz M (1991) Libellus de Medicinalibus Indorum Herbis: Manuscrito azteca de 1552 según traducción latina de Juan Badiano. Instituto Mexicano del Seguro Social, MexicoGoogle Scholar
  63. 63.
    Hernández F (1959) Historia natural de Nueva España. Las Obras Completas de Francisco Hernández en la UNAM. Universidad Nacional Autónoma de México. http://www.franciscohernandez.unam.mx/02_indice_tomo02.html. Accessed 11 June 2017
  64. 64.
    López de Hinojosos AS (1977) Recopilación de cirurgía, con un arte para sangrar muy útil y provechosa. Antonio Ricardo, México, 1578. Edición de la Academia Nacional de Medicina, MéxicoGoogle Scholar
  65. 65.
    Águila Y (1988) “El periodismo científico en Nueva España: Alzáte y Bartolache (1768–1773)”. La América española en la época de las luces. Ediciones de Cultura Hispánica, MadridGoogle Scholar
  66. 66.
    Tedeschi S (2010) “Una literatura entre dilaciones, incertidumbres y ansia de modernidad”. Historia de la cultura literaria en Hispanoamérica I. FCE, MéxicoGoogle Scholar
  67. 67.
    Aceves-Ávila FJ, Fraga A (1997) Las enfermedades reumáticas en el México colonial. Gac Med Mex 133(4):243–250Google Scholar
  68. 68.
    Neri Vela R, Liévano-Madrigal L (2017) Páginas en la historia de la reumatología en México. Rev Fac Med UNAM 60(1):30–37Google Scholar
  69. 69.
    Arce Salinas A, Pascual Ramos V (2015) La certificación del reumatólogo, experiencia en México. Acta Reumatol 2(1):1–4Google Scholar
  70. 70.
    Martínez-Lavín M (2014) Aportaciones de la Reumatología Mexicana al Conocimiento Médico. In: Ruelas Barajas E, Lifshitz Guinzberg A (eds) Estado del Arte de la Medicina 2013–2014: Medicina. Academia Nacional de Medicina, Ciudad de México, pp 29–38Google Scholar
  71. 71.
    Pascual Ramos V, Medrano Ramírez G, Solis Vallejo E et al (2015) Reumatol Clin 11(4):215–220CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Musculoskeletal and Rheumatic DisordersInstituto Nacional de Rehabilitación Luis Guillermo Ibarra IbarraTlalpanMéxico
  2. 2.Saint Luke School of MedicineCiudad de MéxicoMéxico

Personalised recommendations